Swiss pharma Novartis cleared of patent abuse allegations
Competition Commission closes investigation against Novartis
Keystone-SDA
Select your language
Generated with artificial intelligence.
Listening: Swiss pharma Novartis cleared of patent abuse allegations
A two-year investigation of alleged patent abuses by Swiss pharmaceutical company Novartis has been dropped by the Competition Commission (ComCo) without charges.
This content was published on
2 minutes
Keystone-SDA
Deutsch
de
Wettbewerbskommission stellt Untersuchung gegen Novartis ein
Original
The investigations had shown that the Basel-based pharmaceutical company had acted in accordance with antitrust law, the authority announced on Thursday.
ComCo initiated the investigation in September 2022 and also carried out a search at the Novartis headquarters in Basel at the time. The pharmaceutical company had been accused of possibly using a patent for a preparation for the treatment of skin diseases in an unlawful manner to protect itself from competitors.
As part of the investigation, the Competition Commission cooperated with the European Commission.
The investigation has now revealed that Novartis’ conduct was common practice in the area of patent law and also complied with antitrust law, according to the press release. As the indications of abuse have not been confirmed, ComCo is closing the investigation without any consequences.
The European Commission has independently analysed the facts of the case and has come to the same conclusions, the Swiss authority continues.
Translated from German by DeepL/mga
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles. You can find them here.
If you want to know more about how we work, have a look here, and if you have feedback on this news story please write to english@swissinfo.ch.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.